Sudarshan Hebbar
Known title: Chief Medical OfficerCIK: 0001968793
Sudarshan Hebbar's purchase track record
Sudarshan Hebbar has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2025 | CALC | $43K | +23.8% | -73.2% | +5.6% |
| 11/3/2023 | CALC | $99K | +95.8% | +101.4% | +17.6% |
| 5/16/2023 | CALC | $27K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CALC | ▲ Buy | Grant | 124,486 | $100K | 6/25/2026 | View on chart |
| CALC | ▲ Buy | Open Market | 9,563 | $27K | 8/19/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 4,392 | $12K | 8/15/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 1,584 | $4K | 8/14/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 36,000 | $99K | 11/3/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 10,000 | $27K | 5/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.